Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Data from the Phase 3 CASSIOPEIA trial: D-VTd vs. VTd

Philippe Moreau • 14 Jun 2019
EHA 2019
Multiple Myeloma Bortezomib Daratumumab Dexamethasone Thalidomide
CASSIOPEIA

Philippe Moreau, University Hospital, Nantes, France, presents the results of part 1 of the CASSIOPEIA trial (NCT02541383). This trial investigated bortezomib, thalidomide, dexamethasone (VTD) followed by stem cell transplantation, followed by two cycles of consolidation therapy with VTD with or without daratumumab in newly diagnosed multiple myeloma. This press briefing was recorded at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Philippe Moreau

1:15
Overall survival data from the POLLUX trial: DRd versus Rd in patients with R/R multiple myeloma
Philippe Moreau • 15 Feb 2023
4:49
Factors to predict the outcomes of patients with R/R myeloma treated with CAR-T therapy
Philippe Moreau • 15 Feb 2023
3:02
Optimal treatment strategies for multiple myeloma
Philippe Moreau • 10 Sep 2021
1:59
Optimal treatment sequencing for relapsed/refractory myeloma
Philippe Moreau • 10 Sep 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals